ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect ProQR Therapeutics to post earnings of ($0.08) per share and revenue of $6.1180 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 12:30 PM ET.

ProQR Therapeutics Stock Up 13.3%

Shares of NASDAQ:PRQR opened at $1.70 on Thursday. The firm has a market cap of $178.86 million, a price-to-earnings ratio of -3.62 and a beta of 0.21. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The company’s fifty day simple moving average is $1.68 and its 200 day simple moving average is $2.08.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in ProQR Therapeutics in the fourth quarter worth $35,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $51,000. Simplex Trading LLC lifted its position in shares of ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 44,169 shares during the last quarter. Finally, Persistent Asset Partners Ltd lifted its position in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after buying an additional 8,874 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

PRQR has been the subject of several recent research reports. Zacks Research upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ProQR Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $7.14.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.